Cargando…

Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model

Blockade of PD-L1 with specific monoclonal antibodies (anti-PD-L1) represents a therapeutic strategy to increase the capability of the immune system to modulate the tumor immune-resistance. The relationship between anti-PD-L1 tumor exposition and anti-tumor effect represents a challenge that has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contreras, Ana M., Merino, María, Vasquez, Marcos, Trocóniz, Iñaki F., Berraondo, Pedro, Garrido, María J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363557/ https://www.ncbi.nlm.nih.gov/pubmed/27764774 http://dx.doi.org/10.18632/oncotarget.12727

Ejemplares similares

Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
por: Merino, María, et al.
Publicado: (2021)

Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1
por: Zalba, Sara, et al.
Publicado: (2021)

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors
por: Sancho-Araiz, Aymara, et al.
Publicado: (2021)

Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model
por: Vasquez, Marcos, et al.
Publicado: (2016)

Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Myeloid-derived cells are key targets of tumor immunotherapy
por: Medina-Echeverz, José, et al.
Publicado: (2014)

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2023)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Nanometer-scale distribution of PD-1 in the melanoma tumor microenvironment
por: Comerci, Colin J, et al.
Publicado: (2023)

Experience with health care integration in Bidasoa integrated health organisation: development of the continuity of care unit/Experiencia de integración en la Organización Sanitaria Integrada Bidasoa: desarrollo de la Unidad de Continuidad Asistencial
por: Zabalegui, Iñaki Berraondo
Publicado: (2012)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Primary retroperitoneal neuroendocrine tumor with nonspecific presentation: A case report
por: Taei, Tareq Hamed Al, et al.
Publicado: (2020)

Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy
por: Irurzun-Arana, Itziar, et al.
Publicado: (2020)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
por: Sorroche, Bruna Pereira, et al.
Publicado: (2023)

Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I
por: Parra-Guillen, Zinnia Patricia, et al.
Publicado: (2012)

CYTOSTATIC ELIMINATION OF SYNGENEIC RAT TUMOR CELLS IN VITRO BY NONSPECIFICALLY ACTIVATED MACROPHAGES
por: Keller, R.
Publicado: (1973)

The Molecular Heterogeneity of Nonspecific Cross‐reacting Antigen Synthesized by Tumor Cells and Granulocytes
por: Kuroki, Motomu, et al.
Publicado: (1988)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Psychological Correlates of Nonspecific Electrodermal Responses
por: Bari, Dindar S.
Publicado: (2019)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model
por: Vitale, Maria, et al.
Publicado: (2022)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas
por: Alos, Llucia, et al.
Publicado: (2020)

Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
por: Vautrot, Valentin, et al.
Publicado: (2021)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8(+) T cells eradicates peritoneal metastases in mouse models
por: Di Trani, Claudia Augusta, et al.
Publicado: (2022)

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
por: Gupta, Harshita B, et al.
Publicado: (2016)

T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites
Publicado: (1977)

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
por: Diefenbach, Russell J, et al.
Publicado: (2020)

Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells
por: Fankhauser, Reilly, et al.
Publicado: (2022)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Ravindran Menon, Dinoop, et al.
Publicado: (2021)

Tumor Apolipoprotein E is a key checkpoint blocking anti-tumor immunity in mouse melanoma
por: Wu, Xiaofang, et al.
Publicado: (2022)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
por: Wang, Xuanyi, et al.
Publicado: (2020)

Melanocytic matricoma: a rare tumor that can mimic melanoma()
por: Aranguren-López, Iñigo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57sv9184l76l67d5q9nopa679p